Member Exclusive

NS5A inhibitors distinguish half-life differences between HCV strains

Researchers at the University of North Carolina (Chapel Hill, NC, USA) have identified how NS5A inhibitors interact with hepatitis C virus, and their findings show a difference between strains of HCV, which could help provide more effective therapies against a broader range of viruses.

Go to the profile of Peter Brown
Jun 19, 2017

Please sign in or register for FREE

Register to MedChemNet – the medicinal chemistry network

MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.


No comments yet. Start the conversation...